Funder: Breakthrough T1D

Due Dates: October 29, 2025 (LOI) | January 13, 2026 (Full proposal)

Funding Amounts: Up to $3,000,000 total over 3 years; indirect costs up to 10% (SRAs); smaller budgets considered.

Summary: Supports clinical trials to advance therapies for cardiovascular disease in individuals with type 1 diabetes.

Key Information: LOI approval required before full proposal; both academic and industry applicants eligible.